Stent, MICS duo aids glaucoma

Article

Combination cataract/micro-bypass stent shows excellent efficacy and safety profile

Dr Neuhann presented outcomes from follow-up to 12 months for a personal series of 29 eyes of 22 patients with the stent implanted.

The 1-mm device is placed ab interno into Schlemm's canal, creating a bypass of the trabecular meshwork to improve physiologic aqueous outflow.

Follow-up to 6 months was available for 26 eyes and to 12 months for 19 eyes. Despite perfect stent placement, one patient had no IOP response and went on to shunt surgery.

Reductions in IOP, medication use

Among the rest of the series, no other eye required further surgical intervention, there were no cases of loss of best-corrected visual acuity (BCVA), and all eyes benefited with reductions in IOP and need for medications. While IOP averaged 25.4 mmHg preoperatively with mean medication use of 1.4, at 1 year, most patients had IOP •16 mmHg and were medication-free.

"It is interesting to see where glaucoma surgery may be moving in the future, thanks to the development of safe and effective microsurgical techniques," said Dr Neuhann, medical director, Marienplatz Eye Clinic, Munich, Germany. "In this series, patients achieved better IOP control after surgery while needing fewer medications.

"And although surgeons can expect to encounter some complications with any new technique, so far we have seen none when implanting the trabecular micro-bypass stent during routine phacoemulsification," Dr Neuhann said. "Close follow-up is continuing."

The patients in the series had a mean age of 73 years, 21 had a diagnosis of open-angle glaucoma and eight had pseudoexfoliation glaucoma. Onethird of the eyes had a history of previous glaucoma surgery, including argon laser trabeculoplasty (three eyes), selective laser trabeculoplasty (three eyes), laser peripheral iridotomy (two eyes), and trabeculectomy (four eyes).

Preoperatively, all eyes but one were being managed medically with between one and three medications. For the overall cohort, mean IOP decreased to 14.8 mmHg at 1 week after surgery, was 14.5 mmHg at 3 months, and 15.2 mmHg at 6 months. Topical medications were discontinued after surgery, and at 6 months, the mean number of medications being used was only 0.3. At 6 months, mean IOP was 10.2 mmHg and 77% of eyes were medication-free.

Data were similar for the cohort of eyes with consistent follow-up through 12 months. In this group, mean IOP decreased from 27.1 mmHg preoperatively to 14.6 mmHg at 1 month, and was about 16.5 mmHg at 3 and 6 months. Mean medication use decreased from 1.5 preoperatively to 0.5 at 3 and 6 months.

At 1 year, mean IOP was 10.7 mmHg and patients were on an average of one medication.

"We know that glaucoma is a chronic disease and some progression can be expected," Dr Neuhann said. "Therefore, it is not surprising to see a slight increase in IOP over time. Importantly, however, IOP remained well-controlled with use of fewer medications than at baseline."

Preoperatively, BCVA was 20/40 or better in only 9 (31%) eyes, whereas at 6 months after surgery, 96% of eyes achieved 20/40 or better BCVA and 58% were 20/20 or better.

Surgical technique

Dr Neuhann performed all of the surgeries under topical anaesthesia. The stent comes preloaded in a single-use sterile applicator and is delivered following IOL implantation, after first filling the anterior chamber with viscoelastic.

The stent is placed through the trabecular meshwork into Schlemm's canal under gonioscopic control with access through the same temporal clear corneal microincision used for phacoemulsification.

"For best possible angle visualization, insertion is performed from the temporal side with the gonioscopic lens tilted toward the surgeon and the patient's head tilted away," Dr Neuhann said. "Massaging the vessels in the area outside of the chamber angle causes Schlemm's canal to become colourized with blood and makes its visualization very easy."

Special contributor

Dr Tobias Neuhann is medical director, Marienplatz Eye Clinic, Munich, Germany. He may be reached by Email: neuhann@mac.com

Dr Neuhann has no financial interest in the subject matter.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
© 2025 MJH Life Sciences

All rights reserved.